Pre-Clinical Development of an Innovative Neuroprotective Therapy for Stroke and Neonatal Hypoxic-Ischemic Brain Damage

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

7057.2;5 LSPP-LS

Projekttitel

Pre-Clinical Development of an Innovative Neuroprotective Therapy for Stroke and Neonatal Hypoxic-Ischemic Brain Damage

Projekttitel Englisch

Pre-Clinical Development of an Innovative Neuroprotective Therapy for Stroke and Neonatal Hypoxic-Ischemic Brain Damage

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Pre-Clinical Development of an Innovative Neuroprotective Therapy for Stroke and Neonatal Hypoxic-Ischemic Brain Damage
Abstract (Englisch)	Stroke is the third leading cause of disability and mortality in industrialized countries, and perinatal hypoxia-ischemia leads to permanent brain damage in 0.3% of births. The devastating consequences of these conditions are due to massive cell death in the brain. While thrombolysis is now widely used in selected ischemic stroke patients in the acute phase, the use of neuroprotectants has so far failed to prove beneficial in clinical practice. Two main reasons may explain these failures: first, there is an inherent toxicity of the molecules used that generally interfere with the normal functioning of the brain; and second, these molecules are largely ineffective when given more than two hours after the onset of ischemia. We have recently developed a novel cell-permeable peptide, XG-102, that has been shown to protect animal models with unprecedented efficacy. It appears to be devoid of apparent toxicity and has an exceptionally long therapeutic window, being effective even when administered 6-12 hours after stroke onset in mice and rats. This time-window should allow patients reaching medical centers to be effectively treated (Nature Medicine, 2003 Sep;9(9):1180-6). We herein propose to conduct the pre-clinical studies necessary for the XG-102 molecule to enter clinical phases for both stroke and perinatal hypoxia-ischemia.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Pre-Clinical Development of an Innovative Neuroprotective Therapy for Stroke and Neonatal Hypoxic-Ischemic Brain Damage

Abstract
(Englisch)

Stroke is the third leading cause of disability and mortality in industrialized countries, and perinatal hypoxia-ischemia leads to permanent brain damage in 0.3% of births. The devastating consequences of these conditions are due to massive cell death in the brain. While thrombolysis is now widely used in selected ischemic stroke patients in the acute phase, the use of neuroprotectants has so far failed to prove beneficial in clinical practice. Two main reasons may explain these failures: first, there is an inherent toxicity of the molecules used that generally interfere with the normal functioning of the brain; and second, these molecules are largely ineffective when given more than two hours after the onset of ischemia. We have recently developed a novel cell-permeable peptide, XG-102, that has been shown to protect animal models with unprecedented efficacy. It appears to be devoid of apparent toxicity and has an exceptionally long therapeutic window, being effective even when administered 6-12 hours after stroke onset in mice and rats. This time-window should allow patients reaching medical centers to be effectively treated (Nature Medicine, 2003 Sep;9(9):1180-6). We herein propose to conduct the pre-clinical studies necessary for the XG-102 molecule to enter clinical phases for both stroke and perinatal hypoxia-ischemia.